Letter Sequence RAI |
---|
EPID:L-2019-NEW-0004, Shine Medical Technologies, LLC Application for an Operating License (Approved, Closed) |
Initiation
- Request, Request, Request, Request, Request, Request, Request, Request, Request, Request, Request, Request, Request, Request, Request, Request
- Acceptance, Acceptance
- Supplement, Supplement, Supplement, Supplement, Supplement, Supplement, Supplement, Supplement, Supplement, Supplement, Supplement, Supplement
Results
Other: ML19235A308, ML19324F963, ML20057F950, ML20114E315, ML20126G523, ML20226A262, ML21029A103, ML21053A261, ML21089A228, ML21089A334, ML21096A250, ML21130A314, ML21145A060, ML21161A115, ML21209A997, ML21210A438, ML22042A018, ML22075A331, ML22075A336, ML22095A067, ML22124A073, ML22125A040, ML22152A108, ML22187A134, ML22206A208, ML22216A112, ML22220A261, ML22308A233, ML22322A212, ML22322A223, ML22347A177, ML22347A214, ML22348A067, ML22348A070, ML22348A072, ML23006A185
|
MONTHYEARML19211C0442019-07-17017 July 2019 Shine Medical Technologies, LLC Application for an Operating License Project stage: Request ML19211C1432019-07-17017 July 2019 Shine Medical Technologies, LLC Application for an Operating License Project stage: Request ML19235A3082019-09-0505 September 2019 Shine Medical Technologies, LLC - Cover Letter for Notice of Receipt and Availability of Operating License Application Project stage: Other ML19276D4112019-10-0808 October 2019 Shine Medical Technologies, LLC - Acceptance for Docketing Letter Project stage: Acceptance Review ML19276D4092019-10-0808 October 2019 Shine Medical Technologies, LLC - Operating License Application Acceptance Review Results Project stage: Request ML19276D4102019-10-0808 October 2019 Shine Medical Technologies, LLC - Acceptance for Docketing Federal Register Notice Project stage: Acceptance Review ML19337A2752019-11-14014 November 2019 Shine Medical Technologies, LLC Supplement 1 to Final Safety Analysis Report Project stage: Request ML19353C6872019-12-19019 December 2019 Environmental Site Audit Regarding Shine Medical Technologies, LLC - Proposed Medical Isotope Production Facility Project stage: Request ML19324F9622020-01-0202 January 2020, 6 January 2020 Shine Medical Technologies, LLC - Notice of Opportunity for Hearing and Petition for Leave to Intervene Project stage: Request ML19324F9632020-01-0202 January 2020 Shine Medical Technologies, LLC - Cover Letter for Notice of Opportunity for Hearing and Petition for Leave to Intervene Project stage: Other ML20057F9502020-03-0606 March 2020 Shine Medical Technologies, LLC - Instrumentation and Control Regulatory Audit Plan Project stage: Other ML20105A2952020-03-27027 March 2020 Shine Medical Technologies, LLC, Supplement 2 to License Application, Rev.2 to Final Safety Analysis Report Project stage: Supplement ML20114E3152020-04-30030 April 2020 Shine Medical Technologies, LLC - Operating License Application Technical Review Schedule Project stage: Other ML20126G5232020-05-0707 May 2020 Shine Medical Technologies, LLC - Regulatory Audit Plan Related to Electrical Power Systems Project stage: Other ML20226A2622020-08-14014 August 2020 Shine Medical Technologies, LLC - Accident Analysis and Criticality Safety Audit Plan Project stage: Other ML20255A0272020-08-28028 August 2020 Shine Medical Technologies, LLC Operating License Application Response to Request for Additional Information and Supplement No. 3 Project stage: Supplement ML21309A0192020-10-16016 October 2020 Shine Medical Technologies, LLC - Request for Additional Information Related to Chapters 2, 3, and 8 Project stage: RAI ML20311A1242020-10-30030 October 2020 Shine Medical Technologies, LLC, Operating License Application Supplement No. 4 Submittal of a Revision to the Shine Physical Security Plan Project stage: Supplement ML21309A0232020-11-10010 November 2020 Shine Medical Technologies, LLC - Request for Additional Information Related to Chapters 6 and 13 Project stage: RAI ML20325A0262020-11-13013 November 2020 Submittal of a Mark-Up to the Draft NRG-Proposed SHINE-Specific Security Measures Project stage: Request ML20357A0862020-12-10010 December 2020 Enclosure 1 - Final Safety Analysis Report Change Summary Project stage: Request ML21011A2242020-12-15015 December 2020 Shine Medical Technologies, LLC - Operating License Application Supplement No. 6 and Response to Request for Additional Information Project stage: Supplement ML20352A2252020-12-18018 December 2020 Shine Environmental RAIs - Cumulative Impacts Project stage: RAI ML21309A0442021-01-27027 January 2021 Shine Medical Technologies, LLC - Request for Additional Information Related to Chapters 9 and 11 Project stage: RAI ML21019A1592021-01-27027 January 2021 Public Meeting Summary January 12 2021 Project stage: Meeting ML21029A1032021-01-29029 January 2021 Enclosure 1 - Response to Final Safety Analysis Report Chapters 2, 3, and 8 Requests for Additional Information Project stage: Other ML21029A1022021-01-29029 January 2021 Shine Medical Technologies, LLC Operating License Application Response to Request for Additional Information Project stage: Response to RAI ML21029A0382021-01-29029 January 2021 Request for Exemption from Criticality Accident Alarm System Monitoring Requirements for the Shine Irradiation Unit Cells and Material Staging Building Project stage: Request ML21057A0052021-02-26026 February 2021 Shine Medical Technologies. LLC Application for an Operating License Commitment Change Related to the Submission of a Revision to the Technical Specifications Project stage: Request ML21053A2612021-03-11011 March 2021 Shine Medical Technologies - Geotechnical Audit Plan Project stage: Other ML21075A0122021-03-16016 March 2021 Shine Medical Technologies, LLC - Application for an Operating License, Revision 1 of Shine Response to Request for Additional Information 2.4-1 Project stage: Response to RAI ML21095A2142021-03-23023 March 2021 Shine Medical Technologies, LLC, Revisions to Final Safety Analysis Report, Chapter 6, Engineered Safety Features Project stage: Request ML21095A2222021-03-23023 March 2021 Shine Medical Technologies, LLC, Revisions to Final Safety Analysis Report, Chapter 5, Cooling Systems Project stage: Request ML21095A2292021-03-23023 March 2021 Shine Medical Technologies, LLC, Response to Request for Additional Information and Supplement No. 7 Project stage: Supplement ML21095A2352021-03-23023 March 2021 Shine Medical Technologies, LLC, Cover Letter for Response to Request Tor Additional Information and Supplement No. 7 Project stage: Supplement ML21089A3342021-04-0707 April 2021 Shine Medical Technologies, LLC - Summary of Audit Related to Geotechnical Topics Project stage: Other ML21089A0012021-04-0808 April 2021 Shine Medical Technologies, LLC - Request for Additional Information Related to Meteorological Data, Cooling Systems, and Physical Security Project stage: RAI ML21096A2502021-04-0808 April 2021 Shine Medical Technologies - Fire Protection Audit Plan Project stage: Other ML21106A1362021-04-16016 April 2021 Shine Medical Technologies, LLC Application for an Operating License Revision 1 of Shine Response to Request for Additional Information 3.4-6 Project stage: Response to RAI ML21089A2282021-04-21021 April 2021 Shine Medical Technologies, LLC - Physical Security Plan Audit Summary Project stage: Other ML21130A3132021-05-12012 May 2021 Shine Medical Technologies, LLC - Instrumentation and Control Systems Audit Topics Enclosure 2 Project stage: Request ML21130A3142021-05-12012 May 2021 Shine Medical Technologies, LLC - Instrumentation and Control Systems Audit Plan Project stage: Other ML21145A0602021-06-0202 June 2021 Shine Medical Technologies - Ch 6 8 13 and Exemption RAI Project stage: Other ML21161A1162021-06-10010 June 2021 Shine Medical Technologies, LLC - Cyber Security Audit Plan W/ 2 Encl Project stage: Request ML21161A1152021-06-10010 June 2021 Shine Medical Tech Ltr - Cyber Security Audit Plan Enclosure 1 Project stage: Other ML21162A3182021-07-0101 July 2021 Shine Medical Technologies, LLC - Request for Additional Information Related to Fire Protection Project stage: RAI ML21172A1952021-07-0101 July 2021 Shine Medical Technologies, LLC - Request for Additional Information Related to Instrumentation and Control Systems Project stage: RAI ML21208A1352021-07-27027 July 2021 Shine Medical Technologies, LLC Application for an Operating License Response to Request for Additional Information Project stage: Response to RAI ML21209A9972021-08-0303 August 2021 Shine Medical Technologies, LLC - Update to Operating License Application Technical Review Schedule Project stage: Other ML21210A4382021-08-13013 August 2021 Shine Medical Technologies, LLC - Cyber Security RAI Project stage: Other 2020-08-14
[Table View] |
|
---|
Category:Letter
MONTHYEARML23229A0202023-08-17017 August 2023 Periodic Report Required by the License Conditions in Section 3.D.(1) of CPMIF-001 ML23087A2272023-05-0505 May 2023 Shine Technologies, LLC - Issuance of Amendment No. 4 to Construction Permit No. CPMIF-001 for the Receipt and Possession of Contained Special Nuclear Material ML23086C0502023-04-27027 April 2023 Shine Technologies, LLC - Letter, Environmental Assessment and Finding of No Significant Impact ML23088A3382023-04-0505 April 2023 Shine Technologies, LLC - Review of the Physical Security Plan in Support of an Operating License for a Medical Radioisotope Production Facility ML23010A1982023-02-24024 February 2023 Shine Technologies, LLC - Letter: Safety Evaluation Report for the Shine Medical Radioisotope Production Facility Operating License Application ML23048A2442023-02-17017 February 2023 Shine Technologies, LLC Request to Amend Construction Permit No. CPMIF-001 Response to Request for Additional Information ML23034A1872023-02-0303 February 2023 Shine Medical Technologies, LLC Notice of Availability of Environmental Impact Statement Supplement Related to the Operating License for the Shine Medical Isotope Production Facility (Docket Number: 50-608) ML23010A2382023-02-0303 February 2023 Shine Technologies, LLC - Individual Notice of Consideration FRN Letter ML23023A0942023-02-0202 February 2023 Notice of Availability of the Environmental Impact Statement Supplement Related to the Operating License for the Shine Medical Isotope Production Facility ML23023A0922023-02-0202 February 2023 Notice of Availability of the Environmental Impact Statement Supplement Related to the Operating License for the Shine Medical Isotope Production Facility ML23023A0862023-02-0202 February 2023 Notice of Availability of the Environmental Impact Statement Supplement Related to the Operating License for the Shine Medical Isotope Production Facility ML23024A1682023-02-0101 February 2023 Letter to Ken Westlake, EPA Region 5 - Issuance of Final EIS Supplement Related to the Operating License ML23024A1742023-02-0101 February 2023 Dr. Gregory Piefer, Chief Executive Officer - Issuance of Final EIS Supplement Related to the Operating License ML22287A1852023-02-0101 February 2023 Shine Technologies, LLC Regulatory Report on the Audit of Phased Startup Operations Application Supplement ML22308A2332023-01-0909 January 2023 Shine Technologies LLC - Regulatory Audit Report for Chapter 8 - Irradiation Facility and Radioisotope Production Facility Electrical Power Systems ML22347A2142023-01-0404 January 2023 Shine Technologies LLC - Regulatory Audit Report for I&C Combined Sessions ML22356A1932022-12-22022 December 2022 Shine Technologies, LLC Application for an Operating License - Response to Request for Confirmatory Information ML22347A1772022-12-14014 December 2022 Shine Technologies LLC - Regulatory Audit Report for Programmable Logic Lifecycle ML22301A1492022-12-0707 December 2022 Shine Technologies, LLC - Regulatory Audit Report for Chapter 13 - Accident Analysis and Criticality Safety ML22322A2122022-12-0202 December 2022 Shine Medical Technologies - Cybersecurity Audit Summary Report ML22322A2232022-12-0202 December 2022 Shine Medical Technologies - Fire Protection Audit Summary Report ML22348A0672022-12-0101 December 2022 Shine Technologies, LLC - Request for Confirmatory Information Related to Instrumentation and Control Systems ML22335A5722022-12-0101 December 2022 Shine Technologies, LLC Application for an Operating License Response to Request for Confirmatory Information ML22292A3192022-11-30030 November 2022 Shine Medical Technologies, LLC Issuance of Order and Amendment No. 3 to Construction Permit No. CPMIF-001 ML22318A1782022-11-14014 November 2022 Shine Technologies, LLC Application for an Operating License Response to Request for Confirmatory Information ML22304A1262022-10-31031 October 2022 Shine Technologies, LLC Application for an Operating License Response to Request for Confirmatory Information ML22279A9512022-10-0606 October 2022 Shine Technologies, LLC Request to Amend Construction Permit No. CPMIF-001 ML22271A9632022-09-28028 September 2022 Shine Technologies, LLC Application for an Operating License Supplement No. 31 Revision to the Phased Startup Operations Application Supplement ML22263A3442022-09-20020 September 2022 Shine Technologies, LLC Application for an Operating License - Response to Request for Additional Information ML22263A0272022-09-19019 September 2022 Shine Technologies, LLC - Application for an Operating License - Response to Request for Confirmatory Information ML22220A2612022-09-12012 September 2022 Shine Technologies LLC - Regulatory Report on the Audit Chapter 14, Technical Specifications ML22251A3272022-09-0808 September 2022 Shine Technologies, LLC Application for an Operating License Revision 1 of Shine Response to Requests for Additional Information 7-38, 7-40, and 7-48 ML22249A1252022-08-31031 August 2022 Shine Technologies, LLC Final Safety Analysis Report - Application for an Operating License Supplement No. 30, Cover Letter ML22105A1102022-08-26026 August 2022 Shine Medical Technologies LLC - Request for Additional Information Related to the OGC Review of Phrase Approach ML22061A2122022-08-24024 August 2022 Shine Medical Technologies LLC - Regulatory Audit Plan for Phased Approach - Session 1 ML22213A0492022-08-0101 August 2022 Shine Technologies, LLC Application for an Operating License Response to Request for Confirmatory Information ML22187A1342022-08-0101 August 2022 Shine Technologies, LLC - Update to Operating License Application Technical Review Schedule ML22206A2082022-07-27027 July 2022 Shine Medical Technologies, LLC - Request for Confirmatory Information Related to Radiation Protection Program and Waste Management ML22207A0062022-07-26026 July 2022 Shine Technologies, LLC Application for an Operating License Supplement No. 29 ML22202A4492022-07-21021 July 2022 Shine Technologies, LLC Operating License Application Supplement No. 28 - Submittal of a Revision to the Shine Emergency Plan ML22188A2412022-07-14014 July 2022 Meeting with Shine Medical Technologies, LLC (EPID No. L-2019-NEW-0004), to Discuss Development of Shine'S Cybersecurity Program for It'S Medical Isotope Production Facility ML22175A0392022-07-11011 July 2022 Letter to Reid Nelson, Achp Notice of Availability and Request for Comments on the Draft EIS Supplement Related to the Operating License for the Shine Facility ML22175A0542022-07-0808 July 2022 Letter to Gregory Piefer - Notice of Availability of the Draft EIS Supplement Related to the Operating License for the Shine Medical Isotope Production Facility ML22175A0912022-07-0808 July 2022 Notice of Availability and Request for Comments on the Draft Environmental Impact Statement Supplement Related to the Operating License for the Shine (Multiple Tribal Letters) ML22175A0772022-07-0808 July 2022 Letter to Daina Penkiunas - Notice of Availability and Request for Comments on the Draft EIS Supplement Related to the Operating License for the Shine Facility ML22175A0632022-07-0808 July 2022 Letter to Ken Westlake, EPA Region 5 - Notice of Availability and Request for Comments on the Draft EIS Supplement Related to the Operating License for the Shine Facility ML22188A1942022-07-0707 July 2022 Shine Technologies, LLC, Application for an Operating License Supplement No. 27 ML22188A0562022-07-0707 July 2022 Shine Technologies, LLC Operating License Application Supplement No. 26 Submittal of a Revision to the Shine Material Control and Accounting Plan ML22223A0662022-07-0606 July 2022 Shine Technologies, LLC, Application for an Operating License, Revision 1 of the Response to Requests for Additional Information Related to Cyber Security ML22175A0742022-07-0101 July 2022 Letter to Mary Buelow Maintenance of Reference Materials at the Hedberg Public Library for the Environmental Review of Shine Medical Technologies, LLC Operating License Application 2023-08-17
[Table view] Category:Request for Additional Information (RAI)
MONTHYEARML23041A0402023-02-0909 February 2023 NRR E-mail Capture - Request for Additional Information Construction Permit (Cp), License Amendment Request (LAR) ML22348A0672022-12-0101 December 2022 Shine Technologies, LLC - Request for Confirmatory Information Related to Instrumentation and Control Systems ML22348A0702022-11-10010 November 2022 (E-MAIL) Shine Medical Technologies, LLC Request for Confirmatory Information Related to Instrumentation and Control Systems ML22348A0722022-10-28028 October 2022 (Email) Shine Medical Technologies, LLC Request for Confirmatory Information Related to Accident Analysis ML22105A1102022-08-26026 August 2022 Shine Medical Technologies LLC - Request for Additional Information Related to the OGC Review of Phrase Approach ML22063A7042022-05-0606 May 2022 Shine Medical Technologies, LLC - Request for Additional Information Related to the Phased Approach ML22088A1662022-04-18018 April 2022 Shine Medical Technologies, LLC - Request for Additional Information Related to the Process Integrated Control System ML22012A2032022-01-27027 January 2022 Shine Medical Technologies, LLC - Request for Additional Information Related to the Neutron Flux Detection System ML22007A2172022-01-11011 January 2022 Shine Medical Technologies, LLC - Request for Additional Information Related to Instrumentation and Control Systems ML21355A3602021-12-23023 December 2021 Shine Medical Technologies, LLC - Request for Additional Information Related to Radiation Damage ML21280A3382021-10-22022 October 2021 Shine Medical Technologies, Llc Request for Additional Information Related to Operator Training and Requalification Program ML21252A7532021-09-29029 September 2021 Shine Medical Technologies, LLC - Request for Additional Information Related to Instrumentation and Control Systems ML21210A4382021-08-13013 August 2021 Shine Medical Technologies, LLC - Cyber Security RAI ML21162A3182021-07-0101 July 2021 Shine Medical Technologies, LLC - Request for Additional Information Related to Fire Protection ML21172A1952021-07-0101 July 2021 Shine Medical Technologies, LLC - Request for Additional Information Related to Instrumentation and Control Systems ML21173A0122021-06-28028 June 2021 Shine Medical Technologies - Structural RAIs ML21145A0602021-06-0202 June 2021 Shine Medical Technologies - Ch 6 8 13 and Exemption RAI ML21089A0012021-04-0808 April 2021 Shine Medical Technologies, LLC - Request for Additional Information Related to Meteorological Data, Cooling Systems, and Physical Security ML21309A0442021-01-27027 January 2021 Shine Medical Technologies, LLC - Request for Additional Information Related to Chapters 9 and 11 ML20352A2252020-12-18018 December 2020 Shine Environmental RAIs - Cumulative Impacts ML21309A0232020-11-10010 November 2020 Shine Medical Technologies, LLC - Request for Additional Information Related to Chapters 6 and 13 ML21309A0192020-10-16016 October 2020 Shine Medical Technologies, LLC - Request for Additional Information Related to Chapters 2, 3, and 8 ML20148M2802020-05-26026 May 2020 Request for Additional Information Related to Shine Medical Technologies, LLC Operating License Application (Enclosure) ML20092L5922020-04-14014 April 2020 Letter to G. Piefer Clarification on Request for Additional Information Responses for Environmental Review of the Shine Medical Technologies, LLC - Proposed Medical Isotope Production Facility Operating License Application (Dkt No. 50-608) ML19024A5302019-02-13013 February 2019 Shine Medical Technologies, Inc. - Request for Additional Information Regarding the Application for Indirect License Transfer and Conforming Amendment ML17031A4432017-02-0606 February 2017 Shine Medical Technologies, Inc. - Request for Additional Information Regarding Safeguards Information Protection Program ML17031A4402017-01-26026 January 2017 Draft Request for Additional Information Regarding Shine SGI Protection Program ML17031A4392017-01-26026 January 2017 Review of Shine SGI Protection Program Procedures (E-mail) ML15259A1642015-09-24024 September 2015 Shine Medical Technologies, Inc., - Request for Additional Information Regarding Application for Construction Permit ML15244A7712015-08-27027 August 2015 Draft Request for Additional Information Shine Medical Technologies, Inc. Preliminary Safety Analysis Report Supporting a Construction Permit Application ML15099A6072015-04-15015 April 2015 Shine Medical Technologies, Inc., - Request for Additional Information Regarding Application for Construction Permit(Tac Nos. MF2305, MF2307, and MF2308) ML15055A1162015-03-25025 March 2015 Shine Medical Technologies, Inc., - Request for Additional Information Regarding Application for Construction Permit ML15005A4072015-01-0606 January 2015 Shine Medical Technologies, Inc., Request for Additional Information Regarding Application for Construction Permit ML14195A1592014-09-19019 September 2014 Shine Medical Technologies, Inc. - Request for Additional Information Regarding Application for Construction Permit ML14209B0642014-07-24024 July 2014 Shine Revised Draft Request for Additional Information Regarding Application for Construction Permit ML13231A0412013-09-11011 September 2013 Requests for Additional Information Shine 2023-02-09
[Table view] |
Text
UNITED STATES NUCLEAR REGULATORY COMMISSION WASHINGTON, D.C. 20555-0001 April 18, 2022 Dr. Gregory Piefer Chief Executive Officer SHINE Technologies, LLC 3400 Innovation Court Janesville, WI 53546
SUBJECT:
SHINE MEDICAL TECHNOLOGIES, LLC - REQUEST FOR ADDITIONAL INFORMATION RELATED TO THE PROCESS INTEGRATED CONTROL SYSTEM (EPID NO. L-2019-NEW-0004)
Dear Dr. Piefer:
By letter dated July 17, 2019 (Agencywide Documents Access and Management System (ADAMS) Accession No. ML19211C044), as supplemented by letters dated November 14, 2019 (ADAMS Accession No. ML19337A275), March 27, 2020 (ADAMS Accession No. ML20105A295), August 28, 2020 (ADAMS Accession No. ML20255A027),
November 13, 2020 (ADAMS Accession No. ML20325A026), December 10, 2020 (ADAMS Package Accession No. ML20357A084), December 15, 2020 (ADAMS Package Accession No. ML21011A264), March 23, 2021 (ADAMS Accession No. ML21095A235), and January 26, 2022 (ADAMS Package Accession No. ML22034A612), SHINE Medical Technologies, LLC (SHINE) submitted to the U.S. Nuclear Regulatory Commission (NRC) an operating license application for its proposed SHINE Medical Isotope Production Facility in accordance with the requirements contained in Title 10 of the Code of Federal Regulations (10 CFR) Part 50, Domestic Licensing of Production and Utilization Facilities.
During the NRC staffs review of SHINEs operating license application, questions have arisen for which additional information is needed. The enclosed request for additional information (RAI) identifies information needed for the NRC staff to continue its review of the SHINE final safety analysis report, submitted in connection with the operating license application, and prepare a safety evaluation report. The specific technical area of the SHINE operating licenseapplication covered by this RAI is Chapter 7, Instrumentation and Control Systems.
It is requested that SHINE provide responses to the enclosed RAI within 30 days from the date of this letter. To facilitate a timely and complete response to the enclosed RAI, the NRC staff is available to meet with SHINE to clarify the scope of information and level of detail expected to be included in the RAI response. SHINE may coordinate the scheduling and agendas for any such meetings with the responsible project manager assigned to this project.
In accordance with 10 CFR 50.30(b), Oath or affirmation, SHINE must execute its response in a signed original document under oath or affirmation. The response must be submitted in accordance with 10 CFR 50.4, Written communications. Information included in the response that is considered sensitive or proprietary, that SHINE seeks to have withheld from the public,
G. Piefer must be marked in accordance with 10 CFR 2.390, Public inspections, exemptions, requests for withholding. Any information related to safeguards should be submitted in accordance with 10 CFR 73.21, Protection of Safeguards Information: Performance Requirements. Following receipt of the additional information, the NRC staff will continue its evaluation of the subject chapters and technical areas of the SHINE operating license application.
As the NRC staff continues its review of SHINEs operating license application, additional RAIs for other chapters and technical areas may be developed. The NRC staff will transmit any further questions to SHINE under separate correspondence.
If SHINE has any questions, or needs additional time to respond to this request, please contact me at 301-415-2856, or by electronic mail at Michael.Balazik@nrc.gov.
Sincerely, Signed by Balazik, Michael on 04/18/22 Michael Balazik, Project Manager Non-Power Production and Utilization Facility Licensing Branch Division of Advanced Reactors and Non-Power Production and Utilization Facilities Office of Nuclear Reactor Regulation Docket No. 50-608 Construction Permit No. CPMIF-001
Enclosure:
As stated cc: See next page
SHINE Medical Technologies, LLC Docket No. 50-608 cc:
Jeff Bartelme, Director of Licensing SHINE Technologies, LLC 3400 Innovation Court Janesville, WI 53546 Nathan Schleifer, General Counsel SHINE Technologies, LLC 3400 Innovation Court Janesville, WI 53546 Christopher Landers, Director, Office of Conversion National Nuclear Security Administration,NA 23 U.S. Department of Energy 1000 Independence Avenue, SW Washington, DC 20585 Mark Paulson, Supervisor Radiation Protection Section Wisconsin Department of Health Services P.O. Box 2659 Madison, WI 53701-2659 Test, Research and Training Reactor Newsletter Attention: Amber Johnson Dept. of Materials Science and Engineering University of Maryland 4418 Stadium Drive College Park, MD 20742-2115 Mark Freitag, City Manager P.O. Box 5005 Janesville, WI 53547-5005 Bill McCoy 1326 Putnam Avenue Janesville, WI 53546 Alfred Lembrich 541 Miller Avenue Janesville, WI 53548
ML22088A166 NRR-088 OFFICE NRR/DANU/PM NRR/DANU/LA NRR/DANU/BC NRR/DANU/DD (A)
NAME MBalaizk NParker JBorromeo SAnderson DATE 4/1/2022 4/5/2022 4/12/2022 4/13/2022 OFFICE NRR/DANU/PM NAME MBalazik DATE 4/18/2022 OFFICE OF NUCLEAR REACTOR REGULATION REQUEST FOR ADDITIONAL INFORMATION REGARDING THE NEUTRON FLUX DETECTION SYSTEM DESCRIBED IN OPERATING LICENSE APPLICATION CONSTRUCTION PERMIT NO. CPMIF-001 SHINE MEDICAL TECHNOLOGIES, LLC SHINE MEDICAL ISOTOPE PRODUCTION FACILITY DOCKET NO. 50-608 By letter dated July 17, 2019 (Agencywide Documents Access and Management System (ADAMS) Accession No. ML19211C044), as supplemented by letters dated November 14, 2019 (ADAMS Accession No. ML19337A275), March 27, 2020 (ADAMS Accession No. ML20105A295), August 28, 2020 (ADAMS Accession No. ML20255A027),
November 13,2020 (ADAMS Accession No. ML20325A026), December 10, 2020 (ADAMS Package Accession No. ML20357A084), December 15, 2020 (ADAMS Package Accession No. ML21011A264), March 23, 2021 (ADAMS Accession No. ML21095A235), and January 26, 2022 (ADAMS Package Accession No. ML22034A612), SHINE Medical Technologies, LLC (SHINE) submitted to the U.S. Nuclear Regulatory Commission (NRC) an operating license application for its proposed SHINE Medical Isotope Production Facility in accordance with the requirements contained in Title 10 of the Code of Federal Regulations (10 CFR) Part 50, Domestic Licensing of Production and Utilization Facilities.
During the NRC staffs review of SHINEs operating license application, questions have arisen for which additional information is needed. The request for additional information (RAI) identifies information needed for the NRC staff to continue its review of the SHINE final safety analysis report (FSAR), submitted in connection with the operating license application, and prepare a safety evaluation report. The specific chapter of the SHINE operating license application covered by this RAI is Chapter 7, Instrumentation and Control Systems.
The SHINE facility includes a process integrated control system (PICS) and the control console and display instrumentation to control and monitor facility systems and components. These include systems and components within the irradiation facility. PICS also provides control and monitoring of the systems and components in the radioisotope production facility (RPF). The functions of the PICS enable the operator to perform irradiation cycles, transfer target solution to and from the irradiation unit as well as throughout the RPF, and interface with the tritium purification system, processes in the supercell, waste handling operations, and the auxiliary systems. The PICS also monitors and controls nonsafety-related vendor provided instrumentation and control (I&C) systems. A portion of the PICS supports the main control board and operator workstations in the facility control room by receiving operator commands and collecting and transmitting facility information to the operators. Also, the main control board and operator workstations can assist operators in performance of normal operations or diverse actuations to the safety systems, if necessary. The NRC staff understands that PICS is designated as non-safety related because its not credited in the accident analysis to prevent of Enclosure
2 mitigate an accident event. However, the FSAR should provide reasonable assurance that (1) the facility can be operated within normal operating ranges without over-reliance of the target solution vessel reactivity protection system (TRPS) and engineered safety features actuation system (ESFAS) to routinely compensate for potential control errors, (2) that failure of any control or auxiliary system, or operator action, does not cause facility conditions more severe than those described in the accident analysis; and (3) that the PICS will prevent (automatically or manually) the TRPS or ESFAS from performing its intended safety function during an analyzed accident event. This includes an understanding of the design processes for demonstrating reliability and design quality. Therefore, consistent with NUREG-1537, Part 2, Reactor Control System, the NRC staff evaluating that the FSAR has (1) analyzed the normal operating characteristics of the facility; (2) described the functions of the PICS and components designed to permit and support normal reactor operations; (3) confirmed that the PICS and its subsystems and components will give all necessary information to the operator or to automatic devices to maintain planned control for the full range of normal reactor operations; (4) the components and devices of the PICS are designed to sense all parameters necessary for facility operation with acceptable accuracy and reliability to transmit the information with high accuracy in a timely fashion; (5) control devices are designed for compatibility with the analyzed dynamic characteristics of the solution vessel; and (6) the design ensures sufficient interlocks, redundancy, and diversity of subsystems to avoid total loss of operating information and control, to limit hazards to personnel, and to ensure compatibility among operating subsystems and components in the event of single isolated malfunctions of equipment.
The NRC staff issued a RAI (ADAMS Accession No. ML20148M279), requesting information to describe how the proposed PICS meets its applicable Design Criteria. The responses to these RAIs were provided in (ADAMS Accession No. ML20255A026), and in the associated updated FSAR. The NRC staff requested this information to verify that there is reasonable assurance that the PICS is appropriately designed and will reliably provide adequate information for operation and control of the SHINE facility, and that applicable regulatory requirements are met.
Applicable Regulatory Requirements and Guidance Documents The I&C systems, as described in the operating license application, are evaluated using the following regulations and guidance:
Section 50.34, Contents of applications; technical information, paragraph (b)(2) of 10 CFR, which requires a description and analysis of the structures, systems, and components of the facility, with emphasis upon performance requirements, the bases, with technical justification therefor, upon which such requirements have been established, and the evaluations required to show that safety functions will be accomplished. The description shall be sufficient to permit understanding of the system designs and their relationship to safety evaluations.
NUREG-1537, Part 1, Guidelines for Preparing and Reviewing Applications for the Licensing of Non-Power Reactors: Format and Content, issued February 1996 (ADAMS Accession No. ML042430055).
NUREG-1537, Part 2, Guidelines for Preparing and Reviewing Applications for the Licensing of Non-Power Reactors: Standard Review Plan and Acceptance Criteria, issued February 1996 (ADAMS Accession No. ML042430048).
3 Chapter 7 - Instrumentation and Control Systems Process Integrated Control System FSAR Section 1.3.3.1, Principal Design Criteria, states:
Principal design criteria for the facility are described in Section 3.1.
FSAR Section 3.1, Design Criteria, includes a statement of the SHINE safety criteria and describes that the general facility design criteria are included in Table 3.1-3, SHINE Design Criteria, and that design criteria specific to each system are include in the FSAR section for that system. Table 3.1-1, Safety-Related Structures, Systems, and Components [(SSC)], identifies the general facility design criteria applicable to each safety-related SSC.
Table 3.1-2, Nonsafety-Related Structures, Systems, and Components, identifies the general facility design criteria applicable to each nonsafety-related SSC. Both tables include a note that addresses SHINE Design Criteria 1-8 (i.e.,
the applicability of SHINE design criteria 1-8 is not addressed in the body of the table).
RAI 7-49 SHINE Design Criteria 1-8 Note 1 of SHINE FSAR Chapter 3, Design of Structures, Systems, and Components, Table 3.1-2, Nonsafety-Related Structures, Systems, and Components, states that [t]he generally-applicable design criteria 1-8 from Table 3.1-3 are not specifically listed. See corresponding FSAR section(s) for detailed discussions of SSC design. SHINE FSAR Section 7.3.2.1, SHINE Facility Design Criteria, and Table 3.1-2 specifies that SHINE Design Criteria 13 is applicable to PICS. However, it is not clear to the NRC staff whether SHINE Design Criteria 1-8 are applicable to the PICS.
Confirm whether SHINE Design Criteria 1-8 are applicable to the PICS. Update the SHINE FSAR to describe the relation of the PICS design bases to the applicable SHINE Design Criteria 1-8.
This information is necessary for the NRC staff to understand the relation of the design bases to the principal design criteria of facility, as required by 10 CFR 50.34.
RAI 7-50 SHINE Design Criteria 13 Applicability to FSAR Chapter 7.6 FSAR Chapter 7.6, Control Console and Display Instruments, Section 7.6.1, Description, includes descriptions of the control room, main control board, workstations, and other control room interface equipment. There is no listing of the Control Console and Display Instruments, system in FSAR Tables 3.1-1 or 3.1-2. SHINE FSAR Section 7.6.2.1, SHINE Facility Design Criteria, states:
There are no SHINE facility design criteria that are uniquely applicable to the control console and display instruments. SHINE FSAR Section 7.1.5, Control Console and Displays, states, in part:
4 The operator workstations and main control board are provided as the HSI subset of components for the FCR. These components are included as part of the PICS and are classified as nonsafety-related.
In addition to the PICS, it appears that SHINE Design Criterion 13 should also be applicable to its control console and display instruments (e.g., operator workstations and main control board) since these instruments are key in monitoring variables and systems important to safety. SHINE Design Criterion 13, Instrumentation and controls, states:
Instrumentation is provided to monitor variables and systems over their anticipated ranges for normal operation, for anticipated transients, and for postulated accidents as appropriate to ensure adequate safety, including those variables and systems that can affect the fission process, the integrity of the primary system boundary, the primary confinement and its associated systems, and the process confinement boundary and its associated systems.
Appropriate controls are provided to maintain these variables and systems within prescribed operating ranges.
To ensure the underlying principles are met for SHINE Design Criterion 13 are satisfied for the control console and display instruments and to verify that appropriate controls are provided to maintain variables and systems within prescribed operating ranges, provide the following:
- 1. Identify any facility variables to be monitored and displayed for the control room operators that are important to the safe operation of the facility in addition to those already identified in Table 7.4-1 and Table 7.5-1 in the FSAR.
- 2. Identify if any of the variables to be monitored and displayed will be used by the control room operators to perform manual protective actions that are credited in the safety analyses.
This information is necessary for the NRC staff to understand the relation of the design bases to the principal design criteria of facility, as required by 10 CFR 50.34.
RAI 7-51 Equipment Qualification NUREG-1537, Part 2, Section 7.3 states, in part, that [t]he RCS should be designed for reliable operation in the normal range of environmental conditions anticipated within the facility.
SHINE FSAR Section 7.3.3.3, Operating Conditions, describes that the PICS is designed to operate under normal environmental and radiological conditions, which are defined in SHINE FSAR Table 7.2-1, Design Radiation Environments, through Table 7.2-6, Primary Cooling Room Interior Design Environmental Parameters.
Describe how SHINE will ensure PICS and its components meet the SHINE defined environmental and radiological conditions for the areas where they would
5 be installed.
The information requested is necessary to support the following evaluation finding in NUREG-1537, Part 2, Section 7.3:
The RCS should be designed for reliable operation in the normal range of environmental conditions anticipated within the facility.
RAI 7-52 SHINE Design Criteria 37 SHINE FSAR Chapter 3.1 contains Shine Design Criterion 37 which states:
Criterion 37 - Criticality control Criticality in the facility is prevented by physical systems or processes and the use of administrative controls. Use of geometrically safe configurations is preferred. Control of criticality adheres to the double contingency principle.
A criticality accident alarm system to detect and alert facility personnel of an inadvertent criticality is provided.
SHINE FSAR Tables 3.1-1 and 3.1-2 state that SHINE Design Criterion 37 applies to the following systems:
Engineered safety features actuation system (ESFAS)
Hot cell fire detection and suppression system (HCFD)
Iodine and xenon purification and packaging (IXP)
Molybdenum extraction and purification system (MEPS)
Radioactive drain system (RDS)
Radioactive liquid waste storage (RLWS)
Target solution preparation system (TSPS)
Target solution staging system (TSSS)
Uranium receipt and storage system (URSS)
Vacuum transfer system (VTS)
Criticality accident alarm system (CAAS)
Facility fire detection and suppression system (FFPS)
Quality control and analytical testing laboratories (LABS)
Solid radioactive waste packaging (SRWP)
The double contingency principle can be defined as:
Process designs should incorporate sufficient factors of safety to require at least two unlikely, independent, and concurrent changes in process conditions before a criticality accident is possible.
Provide the following and update the PICS section of the FSAR, as appropriate:
- 1. Clarify and identify the portions of the systems that conform to the double contingency principle and that are monitored or controlled by PICS.
6
- 2. If the PICS is used to meet the double contingency principle or its failure could adversely affect the ability to meet the double contingency principle, describe (or reference other FSAR section that contain that description) how the associated I&C (including appropriate portions of the PICS system) implements (or supports compliance with) the double contingency principle.
- 3. If the PICS is used to achieve the double contingency principle, describe the technical specification limiting conditions for operations to ensure sufficient operable I&C equipment to ensure the double contingency principle is met in each instance.
- 4. If the PICS is used to achieve the double contingency principle, or if an PICS failure could challenge the double contingency principle, then describe the associated algorithms and implementing equipment.
RAI 7-53 Facility Operating permissive FSAR Chapter 7 does not describe the effect of the facility operating permissive on the PICS or associated controlled systems.
Clarify the functional effect of the facility operating permissive on the PICS and associated controlled systems.
This description is necessary for the NRC staff to understand the interlocks to limit personnel hazards or prevent damage to systems during the full range of normal operations, as required by 10 CFR 50.34.